MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan A. Flores-Montero,

Slides:

Advertisements

Similar presentations

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Advertisements

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.

Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Positioning NK-κB in multiple myeloma

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.

Tax fingerprint in adult T-cell leukemia

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

How I treat elderly patients with myeloma

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Solid cancers after allogeneic hematopoietic cell transplantation

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

by Jonathan N. Hofmann, Linda M. Liao, Michael N

In situ identification of allospecific B cells using pentamers

by Jessica A. Reese, Xiaoning Li, Manfred Hauben, Richard H

Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients by Oluwagbemiga O. Ayoola, Rahman A.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.

Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative.

Anergy: the CLL cell limbo

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis by Julie Støve Bødker, Rasmus Froberg Brøndum,

Activity of eltrombopag in severe aplastic anemia

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation by Wenbin Xiao, Mariko Yabe, Michael.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

by Seth J. Rotz, Nathan Luebbering, Bradley P

by Alex Aleshin, and Peter L. Greenberg

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Impact of somatic and germline mutations on the outcome of systemic mastocytosis by Javier I. Muñoz-González, María Jara-Acevedo, Iván Alvarez-Twose, Jason.

by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation by Wenbin Xiao, Maheetha.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Volume 2(Supplement 1):1-3

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Plasma biomarker concentrations between study groups.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas by Alexandra Nagy, Aparna.

by Christine L. Kempton, and Amanda B. Payne

Volume 2(Supplement 1):46-49

by Michael R. DeBaun, and Ellen Wright Clayton

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia by Prisca Theunissen, Ester Mejstrikova, Lukasz.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma by Tilmann Bochtler, Maximilian Merz,

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Volume 2(Supplement 1):39-41

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Resistance mechanism for ibrutinib in marginal zone lymphoma

Rituximab immunotherapy: it’s getting personal

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,

Volume 2(Supplement 1):4-7

Presentation transcript:

MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan A. Flores-Montero, Qi Gao, Maesa Koeber, Jessica Wardrope, Brian G. M. Durie, Ahmet Dogan, Alberto Orfao, and Ola Landgren BloodAdv Volume 1(12):728-732 May 9, 2017 © 2017 by The American Society of Hematology

Mikhail Roshal et al. Blood Adv 2017;1:728-732 © 2017 by The American Society of Hematology

Comparison of MSKCC single 10-color tube and EuroFlow two 8-color tubes. Comparison of MSKCC single 10-color tube and EuroFlow two 8-color tubes. (A) Total cell acquisition, percentage of (B) total plasma cells (PCs), (C) normal plasma cells, and (D) abnormal plasma cells, along with (E-F) tables containing a summary of the data. Mikhail Roshal et al. Blood Adv 2017;1:728-732 © 2017 by The American Society of Hematology